Dr. Garcia-Sanz on Combination Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

Ramon Garcia-Sanz, MD, PhD
Published: Tuesday, Aug 14, 2018



Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses combination chemotherapy in patients with Hodgkin lymphoma (HL).

Although most cases of HL are curable, there are 20% to 30% of patients who will not be cured after first-line therapy. Salvage chemotherapy and autologous stem cell transplant (ASCT) are the next steps for these patients, says Garcia-Sanz. Of those patients, around 70% will not achieve a complete response (CR), indicating a need for therapies in this setting.

In a study of patients with relapsed/refractory HL, brentuximab vedotin (Adcetris) plus ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) was shown to be safe and effective in remission induction prior to ASCT. Of 66 patients on the study, 60 achieved a sufficient response and moved onto transplant, and 71% of patients achieved a CR before transplant. After transplant, the response rate increased from 71% to 83%, translating to a 3-year progression-free survival of 71%.
SELECTED
LANGUAGE


Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses combination chemotherapy in patients with Hodgkin lymphoma (HL).

Although most cases of HL are curable, there are 20% to 30% of patients who will not be cured after first-line therapy. Salvage chemotherapy and autologous stem cell transplant (ASCT) are the next steps for these patients, says Garcia-Sanz. Of those patients, around 70% will not achieve a complete response (CR), indicating a need for therapies in this setting.

In a study of patients with relapsed/refractory HL, brentuximab vedotin (Adcetris) plus ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) was shown to be safe and effective in remission induction prior to ASCT. Of 66 patients on the study, 60 achieved a sufficient response and moved onto transplant, and 71% of patients achieved a CR before transplant. After transplant, the response rate increased from 71% to 83%, translating to a 3-year progression-free survival of 71%.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x